<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176253</url>
  </required_header>
  <id_info>
    <org_study_id>08078</org_study_id>
    <nct_id>NCT01176253</nct_id>
  </id_info>
  <brief_title>Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)</brief_title>
  <official_title>Detection of Human Beta Cell Death in T1DM by Methylation Specific PCR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the use of methylation-specific PCR (MSP) assays to detect human beta
      cell-specific gene methylation patterns in serial blood samples drawn from newly diagnosed
      Type 1 diabetics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will follow 25 newly diagnosed type 1 diabetic patients from the onset of symptoms
      to one year post-diagnosis. A total of 11 fasting blood draws will be taken, the first near
      the time of diabetes diagnosis, then 2 weeks later, monthly for the next 6 months, and every
      other month until 12 months. Each blood sample will be evaluated by the MSP assay, as well as
      for measurement of fasting plasma glucose, HbA1c, c-peptide, and autoantibodies. The study
      will also need 25 healthy volunteers to help us match some DNA markers needed for this data.
      Healthy volunteers will be se=matched healthy individuals who have one blood sample drawn.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Develop sensitive, specific, and quantitative methylation- specific PCR assays for the detection of human beta cell-specific DNA methylation patterns cells and the onset of metabolic dysregulation.</measure>
    <time_frame>1 year post diagnosis</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Use the assays to detect beta cell destruction throughout the early time-course of type 1 diabetes mellitus</measure>
    <time_frame>1 year post diagnosis</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">6</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>25 newly diagnosed Type 1 diabetics</arm_group_label>
    <description>25 newly diagnosed Type 1 diabetics within onset of symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 healthy volunteers</arm_group_label>
    <description>25 healthy volunteers (age &amp; sex matched)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw</description>
    <arm_group_label>25 newly diagnosed Type 1 diabetics</arm_group_label>
    <arm_group_label>25 healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type I Diabetic, newly diagnosed, &gt;18 years of age
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy volunteers:

          -  Age &gt; 18 years of age,

          -  Otherwise healthy individuals with no cancer and not pregnant.

        Type 1DM:

          -  Newly diagnosed type I diabetes,

          -  Age &gt; 18 years of age,

          -  Otherwise healthy individuals with no severe complications, no cancer, not pregnant,

          -  Willing and able to comply with the scheduled visits to the clinic for blood sampling,

          -  Remain under the continuing care of an Endocrinologist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Ferreri, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center-Department of Diabetes, Endocrinology, &amp; Metabolism</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lo YM. Circulating nucleic acids in plasma and serum: an overview. Ann N Y Acad Sci. 2001 Sep;945:1-7. Review.</citation>
    <PMID>11708462</PMID>
  </reference>
  <reference>
    <citation>Schütz E, Urnovitz HB, Iakoubov L, Schulz-Schaeffer W, Wemheuer W, Brenig B. Bov-tA short interspersed nucleotide element sequences in circulating nucleic acids from sera of cattle with bovine spongiform encephalopathy (BSE) and sera of cattle exposed to BSE. Clin Diagn Lab Immunol. 2005 Jul;12(7):814-20.</citation>
    <PMID>16002628</PMID>
  </reference>
  <reference>
    <citation>Tong YK, Lo YM. Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta. 2006 Jan;363(1-2):187-96. Epub 2005 Aug 26. Review.</citation>
    <PMID>16126188</PMID>
  </reference>
  <reference>
    <citation>Galm O, Herman JG. Methylation-specific polymerase chain reaction. Methods Mol Med. 2005;113:279-91.</citation>
    <PMID>15968111</PMID>
  </reference>
  <reference>
    <citation>Koike H, Ichikawa D, Ikoma H, Otsuji E, Kitamura K, Yamagishi H. Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients. J Surg Oncol. 2004 Sep 15;87(4):182-6.</citation>
    <PMID>15334633</PMID>
  </reference>
  <reference>
    <citation>Liu Q, Sommer SS. Detection of extremely rare alleles by bidirectional pyrophosphorolysis-activated polymerization allele-specific amplification (Bi-PAP-A): measurement of mutation load in mammalian tissues. Biotechniques. 2004 Jan;36(1):156-66.</citation>
    <PMID>14740499</PMID>
  </reference>
  <reference>
    <citation>Gierl MS, Karoulias N, Wende H, Strehle M, Birchmeier C. The zinc-finger factor Insm1 (IA-1) is essential for the development of pancreatic beta cells and intestinal endocrine cells. Genes Dev. 2006 Sep 1;20(17):2465-78.</citation>
    <PMID>16951258</PMID>
  </reference>
  <reference>
    <citation>Wang J, Cortina G, Wu SV, Tran R, Cho JH, Tsai MJ, Bailey TJ, Jamrich M, Ament ME, Treem WR, Hill ID, Vargas JH, Gershman G, Farmer DG, Reyen L, Martín MG. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med. 2006 Jul 20;355(3):270-80.</citation>
    <PMID>16855267</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type I DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

